Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VM202 in amyotrophic lateral sclerosis
NCT02039401Phase 2Completed
- Sponsor
- Helixmith
- Start
- Mar 2014
- Primary completion
- Aug 2015
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
A Phase 2 trial of Engensis in amyotrophic lateral sclerosis (ALS), sponsored by Helixmith. Started Mar 2014; status: completed.
02
Drugs
Engensis
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02039401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02039401.